Table 2. Incidence and maximum toxicity observed during CapIri-RT treatment (n=36 patients).
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
|---|---|---|---|---|
| Haematologic | ||||
| Leucocytopenia | 12 | 7 | 7 | 2 |
| Thrombocytopenia | 2 | — | — | — |
| Anaemia | 23 | 9 | — | — |
| Gastrointestinal | ||||
| Nausea/vomiting | 9 | 10 | 2 | — |
| Mucositis/stomatitis | 2 | — | — | — |
| Diarrhoea | 13 | 15 | 4 | — |
| Proctitis | 11 | 4 | — | — |
| Abdomial cramping | 6 | 4 | — | — |
| Laboratory | ||||
| Hyperbilirubinaemie | 2 | 1 | — | — |
| ALAT/ASAT elevation | 3 | 3 | 1 | — |
| Creatinine elevation | 3 | — | — | — |
| Skin | ||||
| Hand-foot skin reaction | 3 | — | — | — |
| Alopecia | 5 | — | — | — |
| Radiation dermatits | 12 | 7 | — | — |
| Other | ||||
| Fatigue | 11 | 6 | 1 | — |
| Cholinergic syndrome | 2 | — | — | — |
CTC, common toxicity criteria; NCI, National Cancer Institute.
Adverse events are graded according to CTC of the NCI version 2.0.